Your browser is no longer supported. Please, upgrade your browser.
Settings
PPHM Peregrine Pharmaceuticals, Inc. daily Stock Chart
PPHM [NASD]
Peregrine Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.16 Insider Own0.20% Shs Outstand286.92M Perf Week9.26%
Market Cap169.28M Forward P/E- EPS next Y-0.05 Insider Trans0.00% Shs Float270.04M Perf Month-14.49%
Income-39.40M PEG- EPS next Q-0.01 Inst Own10.80% Short Float1.68% Perf Quarter103.45%
Sales58.50M P/S2.89 EPS this Y6.10% Inst Trans0.02% Short Ratio1.19 Perf Half Y73.53%
Book/sh0.15 P/B3.93 EPS next Y58.30% ROA-35.40% Target Price2.00 Perf Year47.50%
Cash/sh0.14 P/C4.08 EPS next 5Y- ROE-89.00% 52W Range0.28 - 0.77 Perf YTD90.32%
Dividend- P/FCF- EPS past 5Y13.10% ROI-112.50% 52W High-23.38% Beta2.06
Dividend %- Quick Ratio0.70 Sales past 5Y27.10% Gross Margin38.10% 52W Low110.71% ATR0.04
Employees281 Current Ratio1.20 Sales Q/Q59.70% Oper. Margin-58.20% RSI (14)47.50 Volatility6.78% 6.54%
OptionableYes Debt/Eq0.00 EPS Q/Q55.90% Profit Margin-65.90% Rel Volume0.43 Prev Close0.58
ShortableYes LT Debt/Eq0.00 EarningsMar 13 AMC Payout- Avg Volume3.81M Price0.59
Recom2.00 SMA20-5.98% SMA50-1.27% SMA20043.52% Volume1,620,738 Change1.72%
Mar-04-16Reiterated FBR Capital Outperform $3.50 → $1
Jul-16-15Initiated Noble Financial Buy $5
Mar-11-14Reiterated MLV & Co Buy $2.50 → $3.50
Sep-27-12Resumed MLV & Co Buy $4.50 → $2
Aug-30-11Initiated JMP Securities Mkt Outperform $5
Apr-11-17 02:23PM  ETFs with exposure to Peregrine Pharmaceuticals, Inc. : April 11, 2017 Capital Cube -8.06%
Apr-04-17 08:05AM  Peregrine Pharmaceuticals Highlights Clinical Data Presentation at AACR 2017 Annual Meeting Supporting Potential of Bavituximab to Enhance Anti-tumor Activity of Immunotherapy GlobeNewswire
08:05AM  Peregrine Pharmaceuticals Highlights Clinical Data Presentation at AACR 2017 Annual Meeting Supporting Potential of Bavituximab to Enhance Anti-tumor Activity of Immunotherapy
Apr-03-17 08:05AM  Peregrine Pharmaceuticals Announces Presentation of Preclinical Study Results Highlighting Potential of PS-Targeting Antibodies to Enhance Anti-Tumor Activity of Adoptive T Cell Transfer Therapy with No Added Off-Target Toxicities GlobeNewswire
Mar-27-17 04:04PM  ETFs with exposure to Peregrine Pharmaceuticals, Inc. : March 27, 2017 Capital Cube
04:04PM  ETFs with exposure to Peregrine Pharmaceuticals, Inc. : March 27, 2017
09:30AM  Biotech Industry Continues to Provide Investors with Gains in 2017: Today's Reports on Peregrine Pharmaceuticals and Novavax Accesswire
Mar-23-17 08:05AM  Avid Bioservices Receives Mutliple 2017 CMO Leadership Awards for Quality, Reliability, Capabilties, Expertise and Compatibility Marketwired
07:05AM  Peregrine Pharmaceuticals Announces Five Abstracts Accepted for Presentation at AACR 2017 Annual Meeting GlobeNewswire
Mar-22-17 10:09AM  Peregrine Pharmaceuticals, Inc. :PPHM-US: Earnings Analysis: Q3, 2017 By the Numbers : March 22, 2017 Capital Cube
10:09AM  Peregrine Pharmaceuticals, Inc. :PPHM-US: Earnings Analysis: Q3, 2017 By the Numbers : March 22, 2017
Mar-17-17 01:04PM  PEREGRINE PHARMACEUTICALS INC Financials
Mar-13-17 04:56PM  Peregrine reports 3Q loss Associated Press +16.92%
04:56PM  Peregrine reports 3Q loss
04:35PM  PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclo
04:05PM  Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2017 and Recent Developments GlobeNewswire
07:07AM  Q3 2017 Peregrine Pharmaceuticals Inc Earnings Release - After Market Close
Mar-09-17 04:27PM  PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -10.29%
04:05PM  Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock GlobeNewswire
09:30AM  Today's Research Reports on Trending Biotech Tickers: Peregrine Pharmaceuticals and Cara Therapeutics Accesswire
Mar-06-17 08:05AM  Peregrine to Report Financial Results for Third Quarter of Fiscal Year 2017 After Market Close on March 13, 2017 GlobeNewswire
Feb-22-17 08:05AM  Avid Bioservices to Participate at Upcoming Life Sciences Industry Conferences GlobeNewswire +10.42%
Feb-10-17 12:43PM  Peregrine Cancer Test Clears Proof of Concept at Investopedia
03:27AM  Can the Rally in Peregrine Pharmaceuticals (PPHM) Shares Continue?
Feb-09-17 08:05AM  Recent Publication Highlights Proof-of-Concept Data Supporting the Diagnostic Potential of Phosphatidylserine-Positive Exosomes in Ovarian Cancer GlobeNewswire +12.50%
Jan-24-17 07:14AM  Peregrine Pharmaceuticals (PPHM) Sees Hammer Chart Pattern: Time to Buy? +6.90%
Jan-20-17 01:48PM  ETFs with exposure to Peregrine Pharmaceuticals, Inc. : January 20, 2017
Jan-17-17 11:08AM  Heat Biologics to reap benefit of new biotech at bizjournals.com
Jan-04-17 11:26AM  ETFs with exposure to Peregrine Pharmaceuticals, Inc. : January 4, 2017
Dec-30-16 04:04PM  Plug Power, Innocoll Drop into Fridays 52-Week Low Club
Dec-23-16 01:05PM  ETFs with exposure to Peregrine Pharmaceuticals, Inc. : December 23, 2016 +9.68%
Dec-22-16 08:15AM  Blog Coverage Lexicon Pharma's Tandem2 Phase 3 Clinical Trial of Sotagliflozin Met its Primary Endpoint Accesswire
Dec-16-16 08:34AM  Peregrine Pharmaceuticals, Inc. :PPHM-US: Earnings Analysis: Q2, 2017 By the Numbers : December 16, 2016
Dec-13-16 03:59PM  Edited Transcript of PPHM earnings conference call or presentation 12-Dec-16 9:30pm GMT -10.81%
11:43AM  ETFs with exposure to Peregrine Pharmaceuticals, Inc. : December 13, 2016
Dec-12-16 04:38PM  PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclo -7.50%
04:16PM  Peregrine reports 2Q loss
04:05PM  Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2017 and Recent Developments GlobeNewswire
07:29AM  Is Peregrine Pharmaceuticals (PPHM) A Good Stock To Buy? at Insider Monkey
07:07AM  Q2 2017 Peregrine Pharmaceuticals Inc Earnings Release - After Market Close
Dec-09-16 08:05AM  Avid Bioservices to Participate at Upcoming Life Sciences Industry Conferences Marketwired +25.00%
Dec-06-16 04:55PM  PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:05PM  Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock GlobeNewswire
Dec-05-16 04:05PM  Peregrine to Report Financial Results for Second Quarter of Fiscal Year 2017 After Market Close on December 12, 2016 GlobeNewswire
Dec-02-16 01:06PM  ETFs with exposure to Peregrine Pharmaceuticals, Inc. : December 2, 2016
Nov-14-16 08:05AM  New Study Demonstrates Anti-Tumor Advantages for Combination Treatment Featuring Peregrine Pharmaceuticals PS-Targeting Antibodies in a Preclinical Melanoma Model GlobeNewswire +9.68%
Oct-24-16 11:54AM  Edited Transcript of PPHM earnings conference call or presentation 8-Sep-16 8:30pm GMT +5.88%
08:05AM  Preclinical Research Demonstrates Peregrine Pharmaceuticals PS-Targeting Antibodies Enhance the Anti-Tumor Activity of PD-L1 Checkpoint Inhibitors in Model of Triple Negative Breast Cancer (TNBC) GlobeNewswire
Oct-23-16 04:23PM  5 Biotech Penny Stocks Smart Money Is Piling On at Insider Monkey
Oct-17-16 10:34AM  ETFs with exposure to Peregrine Pharmaceuticals, Inc. : October 17, 2016
Oct-13-16 04:46PM  PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to
Oct-12-16 02:26PM  PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule -5.13%
Oct-11-16 08:28AM  PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Oct-10-16 08:05AM  Peregrine Pharmaceuticals Reports Top-Line and Initial Biomarker Data from Phase III SUNRISE Trial of Bavituximab in Oral Presentation at European Society for Medical Oncology (ESMO) 2016 Congress GlobeNewswire -9.30%
Oct-03-16 11:18AM  ETFs with exposure to Peregrine Pharmaceuticals, Inc. : October 3, 2016
Sep-27-16 08:05AM  Peregrine Pharmaceuticals Presents Preclinical Data Demonstrating PS-Targeting Antibodies Significantly Enhance the Anti-Tumor Activity of Multiple Checkpoint Targeting Agents in Model of Triple Negative Breast Cancer (TNBC) GlobeNewswire
Sep-26-16 09:55AM  Peregrine Pharmaceuticals, Inc. :PPHM-US: Earnings Analysis: Q1, 2017 By the Numbers : September 26, 2016
Sep-23-16 10:35AM  ETFs with exposure to Peregrine Pharmaceuticals, Inc. : September 23, 2016
Sep-21-16 08:05AM  Peregrine Pharmaceuticals Provides Update on Oral Presentation of Top-Line Data from Phase III SUNRISE Trial of Bavituximab at European Society for Medical Oncology (ESMO) 2016 Congress GlobeNewswire +10.53%
Sep-09-16 10:00PM  Peregrine Results Reaffirm On-Track Revenue Projection (PPHM) at Investopedia -7.14%
Sep-08-16 04:30PM  Peregrine reports 1Q loss
04:18PM  PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclo
04:05PM  Peregrine Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2017 and Recent Developments GlobeNewswire
07:07AM  Q1 2017 Peregrine Pharmaceuticals Inc Earnings Release - After Market Close
Sep-06-16 04:27PM  PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits +5.26%
04:05PM  Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock GlobeNewswire
08:45AM  National Comprehensive Cancer Network (NCCN) Awards Three Grants for Combination Studies of Peregrine Pharmaceuticals Bavituximab in Multiple Cancers GlobeNewswire
Sep-01-16 04:05PM  Peregrine to Report Financial Results for First Quarter of Fiscal Year 2017 After Market Close on September 8, 2016 GlobeNewswire
Aug-29-16 12:00PM  ETFs with exposure to Peregrine Pharmaceuticals, Inc. : August 29, 2016
Aug-18-16 06:46PM  ETFs with exposure to Peregrine Pharmaceuticals, Inc. : August 18, 2016
Aug-15-16 07:02AM  They Developed A Disruptive Drug With Government Funding And Trade Crazy Cheap
Aug-09-16 08:05AM  Avid Bioservices to Participate in Cambridge Healthtech Institutes (CHI) 8th Annual The Bioprocessing Summit GlobeNewswire
Jul-29-16 01:47PM  ETFs with exposure to Peregrine Pharmaceuticals, Inc. : July 29, 2016
Jul-22-16 09:24AM  Peregrine Pharmaceuticals, Inc. :PPHM-US: Earnings Analysis: 2016 By the Numbers : July 22, 2016
Jul-18-16 02:12PM  ETFs with exposure to Peregrine Pharmaceuticals, Inc. : July 18, 2016
Jul-15-16 01:27PM  Edited Transcript of PPHM earnings conference call or presentation 14-Jul-16 8:30pm GMT -9.30%
Jul-14-16 04:39PM  PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclo +10.26%
04:30PM  Peregrine Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today
04:05PM  Peregrine Pharmaceuticals Reports Financial Results for Quarter and Fiscal Year Ended April 30, 2016 and Recent Developments GlobeNewswire
08:05AM  Peregrine Licenses Novel Exosome-Based Cancer Detection and Monitoring Technology from UT Southwestern Medical Center GlobeNewswire
07:07AM  Q4 2016 Peregrine Pharmaceuticals Inc Earnings Release - After Market Close
Jul-12-16 09:10AM  Coverage Initiated on Select Biotech Equities
Jul-07-16 04:05PM  Peregrine to Report Financial Results for the Quarter and Fiscal Year Ended April 30, 2016 After Market Close on July 14, 2016 GlobeNewswire
Jun-03-16 04:39PM  PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
Jun-02-16 04:25PM  PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits +16.28%
04:00PM  Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock GlobeNewswire
08:05AM  Peregrine Pharmaceuticals Provides Corporate Update Highlighting Latest Developments for Contract Manufacturing and Drug Development Businesses GlobeNewswire
May-31-16 08:05AM  Avid Bioservices to Exhibit at the 2016 BIO International Convention Marketwired
May-23-16 08:05AM  Avid Bioservices Appoints Pete Gagnon as Vice President of Process Sciences Marketwired
May-20-16 12:01PM  ETFs with exposure to Peregrine Pharmaceuticals, Inc. : May 20, 2016
May-19-16 04:46PM  Peregrine Pharmaceuticals, Inc. :PPHM-US: Earnings Analysis: Q3, 2016 By the Numbers
Apr-20-16 08:05AM  Preclinical Data Presented at American Association for Cancer Research (AACR) Annual Meeting Demonstrate Enhanced Therapeutic Benefit of Combining a PS-Targeting Antibody With Anti-PD-1 Therapy in Models of Triple Negative Breast Cancer (TN GlobeNewswire
Apr-12-16 04:32PM  PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule
Apr-06-16 01:17PM  Edited Transcript of PPHM earnings conference call or presentation 9-Mar-16 4:30pm GMT
Mar-17-16 06:02AM  PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification t
Mar-09-16 11:30AM  Peregrine Pharmaceuticals Inc Earnings Call scheduled for 11:30 am ET today -6.52%
10:35AM  PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclo
08:13AM  Peregrine reports 3Q loss
08:00AM  Peregrine Pharmaceuticals Reports Financial Results for Third Quarter of Fiscal Year 2016 and Recent Developments GlobeNewswire
Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, researches and develops monoclonal antibodies for the treatment of cancer in the United States. It's lead immunotherapy candidate bavituximab, a monoclonal antibody that targets and binds to phosphatidylserine. The company also provides integrated current good manufacturing practices services from cell line development to commercial bio manufacturing for its third-party customers. In addition, its services comprise cGMP clinical and commercial manufacturing utilizing stainless steel and single use bioreactor technology, purification, bulk packaging, stability testing, regulatory strategy and related support. The company has license agreements with the University of Texas Southwestern Medical Center at Dallas; Genentech, Inc.; Avanir Pharmaceuticals, Inc.; Lonza Biologics; Affitech A/S; Merck KGaA; and National Comprehensive Cancer Network, as well as collaboration agreement with AstraZeneca PLC and Memorial Sloan Kettering Cancer Center. Peregrine Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Tustin, California.